Abstract
CRISPR technology has revolutionised lung cancer research. It can be used to model lung cancer in animals, to find new players in cancer initiation and progression, to diagnose earlier, and even to design novel gene therapies. https://bit.ly/3GPjT6o
Footnotes
Conflict of interest: The authors declare that there are no conflicts of interest.
Support statement: This work was funded by a FIS project (PI20/01500); a Miguel Servet contract co-funded by the Instituto de Salud Carlos III (CP20/00039) and European Social Fund (ESF) “Investing in your future”; and the Emergent Research Group Recognition Award from the University and Research Grants Management Agency of Catalonia (Spain) (2017SRG1620). The research was also supported by CERCA Programme of Generalitat de Catalunya and the IRBLleida – Fundació Dr. Pifarré. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received October 1, 2021.
- Accepted October 27, 2021.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
Jump To
- Article
- Abstract
- Introduction
- How does CRISPR technology work?
- Modelling lung cancer genetically
- Identification of novel genes responsible for lung cancer onset, progression and targeted therapy success
- Diagnosis of lung cancer
- Gene therapy for lung cancer treatment
- Future perspectives
- Shareable PDF
- Footnotes
- References
- Figures & Data
- Info & Metrics